Semipermeable membrane dressings can be used with the nicotine transdermal system and do not interfere with nicotine absorption.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

Adverse skin reactions as a local side effect of nicotine patches sometimes interfere with smoking cessation therapy.

Who Took Part

The abstract describes 28 subjects taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Second, 28 subjects undergoing NP therapy for diagnosed nicotine dependence were randomly assigned into two groups in a crossover design to receive NP over SMD and NP without SMD.

The urinary cotinine levels and skin symptoms were compared between the two treatment groups.

How the Study Was Run

In design terms this was a randomized and crossover study.

The subjects were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

In the crossover set-up each of the subjects took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

First, the urinary cotinine levels were compared in eight nonsmokers that applied NP over SMD and NP without SMD (Study 1).

The urinary cotinine levels were measured using a highly sensitive competitive enzyme immunoassay.

What Was Measured

The subject headings attached to it are Administration, Cutaneous, Bandages, Cell Membrane Permeability, Cotinine, Drug Carriers, Nicotine and Skin Absorption.

What This Means in Plain Language

The paper is a randomized and crossover study of Therapeutic nicotine (patch, non-peptide) in 28 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (Internal medicine (Tokyo, Japan)), a journal based in Japan.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.